AVITA Medical Inc
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound mana…
The business
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.
Small Caps Research
No research on AVITA Medical Inc yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise AVH based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
AVITA Medical Lifts Guidance as Record Quarter Brings Cash Flow Breakeven into View
AVITA Medical lifts 2026 revenue guidance after record Q2 US$21.7m; eyes cash-flow breakeven in Q4 as RECELL-led growth broadens international reach.
AVITA Medical Reports Accelerating Grafting Times in Positive Interim Results for Cohealyx-I Study
AVITA Medical reports Cohealyx-I interim: mean grafting 13.6 days vs 33.2 benchmark; early grafting, strong clinician adoption signals.
AVITA Medical to launch RECELL GO system in US burn centres following FDA approval
Wound care management specialist AVITA Medical (ASX: AVH) has obtained US Food and Drug Administration (FDA) approval for its RECELL GO skin restoration system. RECELL GO is a cell-harvesting device that utilises the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. Chief executive officer Jim Corbett said […]
What are the ASX stocks vulnerable to a ‘short squeeze’?
Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly food for short … er, thought. This month shares in online travel agent Webjet (ASX: WEB) have climbed around 10% as […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.